Treatment with the IL-6 receptor–blocking (IL-6R–blocking) antibody tocilizumab for 24 hours decreased ARG1 expression in IPF PCLS lysates (Figure 5A). This evidence concerns the gene IL6R and idiopathic pulmonary fibrosis.